ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has subscribed to a wealth management product for HK$200 million from Haitong ASM, using its internal surplus cash reserves. The investment is a cash management fund with an expected return of 3-4% per annum and can be redeemed with seven days’ notice. This strategic financial move aims to enhance capital utilization and income from idle funds without impacting the company’s working capital or operations.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.